Scott Berry

Berry Consultants, LLC

Austin, TX

United States

SCHOLARLY PAPERS

3

DOWNLOADS

66

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (3)

1.

A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with BAN2401, an Anti-Aβ Protofibril Antibody

Number of pages: 40 Posted: 29 Sep 2020
Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai Ltd., BioArctic AB, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Eisai, Inc. - Eisai, Inc. - United States, Berry Consultants, LLC, Berry Consultants, LLC, Eisai Ltd., Eisai, Inc. - Eisai, Inc. - United States and Cleveland Clinic - Lou Ruvo Center for Brain Health
Downloads 41 (496,569)

Abstract:

Loading...

Alzheimer's disease, BAN2401, clinical trial, biomarker, ADCOMS, amyloid PET, neurofilament light, neurogranin, p-tau

2.

A Cost/Benefit Analysis of Clinical Trial Designs for Covid-19 Vaccine Candidates

NBER Working Paper No. w27882
Number of pages: 54 Posted: 07 Oct 2020 Last Revised: 08 Mar 2021
affiliation not provided to SSRN, Berry Consultants, LLC, affiliation not provided to SSRN, Pfizer, Inc., Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering, Massachusetts Institute of Technology (MIT) - Laboratory for Financial Engineering and Massachusetts Institute of Technology (MIT) - Computer Science and Artificial Intelligence Laboratory (CSAIL)
Downloads 19 (615,374)

Abstract:

Loading...

3.

Durvalumab With Olaparib and Paclitaxel for High-Risk HER2-Negative Stage II/III Breast Cancer: Results From the Adaptively Randomized I-SPY2 Platform Trial

Number of pages: 41 Posted: 19 Dec 2020
Yale University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Moffitt Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of California, San Diego (UCSD), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), University of Colorado, The University of Minnesota, University of Chicago, Loyola University of Chicago - Stritch School of Medicine, University of Pennsylvania, Oregon Health and Science University, Columbia University, Georgetown University, Wake Forest University, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Alabama at Birmingham, Mayo Clinic, University of California, San Francisco (UCSF), George Mason University, George Mason University, Quantum Leap Healthcare Collaborative, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), Berry Consultants, LLC, Berry Consultants, LLC, Quantum Leap Healthcare Collaborative, University of California, San Francisco (UCSF), Gemini Group, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of California, San Diego (UCSD), University of Texas at Houston - MD Anderson Cancer Center, The University of Minnesota, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), University of Pennsylvania, Berry Consultants, LLC and University of California, San Francisco (UCSF)
Downloads 6 (709,273)

Abstract:

Loading...

Breast cancer; immunotherapy; DNA repair inhibitor; clinical trial